Australia Needs Stronger Leadership For Biotech To Prosper
Executive Summary
As Australia ends a resources boom, a decline in manufacturing has left the country vulnerable, and a concerted investment in biotechnology could transform the country, according to a new report.
You may also be interested in...
Novartis adds novel pain program via $200m Spinifex buy
Executing on its planned strategy for an 'exit' exactly on schedule, Australian/US biotech Spinifex Pharmaceuticals has agreed to be acquired by Novartis for $200m plus undisclosed development and regulatory milestones.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.